Practice patterns in haemophilia A therapy - global progress towards optimal care

被引:147
作者
Geraghty, S
Dunkley, T
Harrington, C
Lindvall, K
Maahs, J
Sek, J
机构
[1] Univ Colorado, Hlth Sci Ctr, Mt States Reg Haemophilia & Thrombosis Ctr, Aurora, CO USA
[2] Queen Elizabeth Hosp, W Midlands Reg Haemophilia Unit, Birmingham B15 2TH, W Midlands, England
[3] Royal Free Hosp, Katherine Dormandy Haemophilia Comprehens Care Ct, London NW3 2QG, England
[4] Malmo Univ Hosp, Dept Coagulat Disorders, Malmo, Sweden
[5] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA
[6] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
关键词
arthropathy; demography; factor VIII; haemophilia A; nursing; prophylaxis;
D O I
10.1111/j.1365-2516.2006.01189.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This paper reports the findings of a global survey of practice patterns for the management of patients with haemophilia A. A total of 147 haemophilia treatment centres worldwide responded to the questionnaire, supplying data for 16 115 patients with haemophilia A. From these responses, 38% (range: 25-48%) of patients were under 18 years old. Almost half (47%) of patients were reported to have mild or moderate haemophilia A, 48% had severe haemophilia A (no inhibitor) and 5% were inhibitor patients. Less than half of patients with severe haemophilia A received prophylactic therapy (37%, excluding inhibitor patients) and 54% received on-demand treatment; the remaining 9% were inhibitor patients. Primary prophylaxis rates for severe haemophilia ranged from 73% in Sweden to 17% in the USA. Most respondents (80%) ranked infrequent bleeds as one of the top five reasons for not administering prophylactic treatment, followed by venous access (60%) and cost (45%). Of patients with severe haemophilia (non-inhibitor), 32% on primary prophylaxis and 27% on secondary prophylaxis had indwelling catheters. Risk of infection and the patient's inability to maintain the line were the key concerns cited by nurses relating to venous access. The mean ratio of nurses to patients with haemophilia A was 1:69 and nurses felt that they were either fully (26%) or mostly (45%) autonomous in assessment and treatment decisions. Results from this current survey suggest that worldwide research should be continued so as to improve outcomes through the identification of optimal treatment protocols for the management of haemophilia A.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 28 条
[1]  
Ahlberg A, 1965, ACTA ORTHOP SCAND S, V77, P99
[2]   Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized [J].
Astermark, J ;
Petrini, P ;
Tengborn, L ;
Schulman, S ;
Ljung, R ;
Berntorp, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :1109-1113
[3]   A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres [J].
Blanchette, VS ;
McCready, M ;
Achonu, C ;
Abdolell, M ;
Rivard, G ;
Manco-Johnson, MJ .
HAEMOPHILIA, 2003, 9 :19-26
[4]  
BLANCHETTE VS, 2003, HAEMOPHILIA S1, V9, P26
[5]   Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States [J].
Butler, RB ;
McClure, W ;
Wulff, K .
HAEMOPHILIA, 2003, 9 (05) :549-554
[6]   On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden:: differences in treatment characteristics and outcome [J].
Carlsson, KS ;
Höjgård, S ;
Glomstein, A ;
Lethagen, S ;
Schulman, S ;
Tengborn, L ;
Lindgren, A ;
Berntorp, E ;
Lindgren, B .
HAEMOPHILIA, 2003, 9 (05) :555-566
[7]   Complications of central venous access devices in paediatric haemophilia patients [J].
Domm, JA ;
Hudson, MG ;
Janco, RL .
HAEMOPHILIA, 2003, 9 (01) :50-56
[8]   Prophylaxis for severe haemophilia: clinical and economical issues [J].
Fischer, K ;
Van den Berg, M .
HAEMOPHILIA, 2003, 9 (04) :376-381
[9]   Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome [J].
Fischer, K ;
Van der Bom, JG ;
Molho, P ;
Negrier, C ;
Mauser-Bunschoten, EP ;
Roosendaal, G ;
De Kleijn, P ;
Grobbee, DE ;
Van den Berg, HM .
HAEMOPHILIA, 2002, 8 (06) :745-752
[10]   Adverse events in the prophylaxis of haemophilia [J].
Giangrande, PLF .
HAEMOPHILIA, 2003, 9 :50-54